Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOXO1 | Q12778 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HPSE | Q9Y251 | 8/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | COMT | P21964 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2740088 | 0.92 | NPC1 (0.67) | FOXO1NPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL2740087 | 0.86 | USP2 (0.67) | FOXO1NPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL2740089 | 0.85 | RAB9A (0.68) | FOXO1NPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL2624736 | 0.83 | FOXO1 (0.70) | FOXO1NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL6246003 | 0.82 | HPSE (0.80) | NPC1RAB9AHPSEPOLBKMT2A | |
| SCHEMBL2739951 | 0.81 | NPC1 (0.61) | FOXO1NPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL14614722 | 0.80 | FOXO1 (0.54) | FOXO1NPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL15045374 | 0.77 | MEN1 (0.69) | NPC1RAB9ASMN1; SMN2POLBKMT2A | |
| SCHEMBL22489169 | 0.75 | NPC1 (0.66) | FOXO1NPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL25426606 | 0.74 | FOXO1 (0.65) | FOXO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9585907-B2 | Methods and compositions for modulating Tau levels | THE J. DAVID GLADSTONE INSTITUTES (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160015733-A1 | METHODS AND COMPOSITIONS FOR MODULATING TAU LEVELS | THE J. DAVID GLADSTONE INSTITUTES | 2016-01-21 | — | — | US | disclosed |
| US-9040521-B2 | Methods and compositions for modulating tau levels | THE J. DAVID GLADSTONE INSTITUTES (US) | 2015-05-26 | — | — | US | disclosed |
| US-8748464-B2 | Use of SIRT1 activators or inhibitors to modulate an immune response | THE J. DAVID GLADSTONE INSTITUTES (US) | 2014-06-10 | — | — | US | disclosed |
| US-20140030295-A1 | Use of Sirt1 Activators or Inhibitors to Modulate an Immune Response | THE J. DAVID GLADSTONE INSTITUTES (US) | 2014-01-30 | — | — | US | disclosed |
| US-20120225864-A1 | Methods and Compositions for Modulating Tau Levels | THE J. DAVID GLADSTONE INSTITUTES | 2012-09-06 | — | — | US | disclosed |
| US-20120197013-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| US-8178536-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8163908-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120022254-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110130387-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20100330114-A1 | Use of SIRT1 Activators or Inhibitors to Modulate an Immune Response | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130387-A1 | SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | FOXO1 105/4885NPC1 3399/4885RAB9A 965/4885 |
| US-20100330114-A1 | Use of SIRT1 Activators or Inhibitors to Modulate an Immune Response | SIRT1, SIRT2, NFATC1 | FOXO1 58/4885NPC1 3045/4885RAB9A 2947/4885 |
| US-20120225864-A1 | Methods and Compositions for Modulating Tau Levels | MAPT, NEFM, PSEN2 | FOXO1 3615/4885NPC1 478/4885RAB9A 3541/4885 |
| US-20140030295-A1 | Use of Sirt1 Activators or Inhibitors to Modulate an Immune Response | SIRT1, SIRT2, NFATC1 | FOXO1 58/4885NPC1 3045/4885RAB9A 2947/4885 |
| US-20120022254-A1 | SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | FOXO1 105/4885NPC1 3399/4885RAB9A 965/4885 |
| US-20120197013-A1 | SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | FOXO1 105/4885NPC1 3399/4885RAB9A 965/4885 |
| US-20160015733-A1 | METHODS AND COMPOSITIONS FOR MODULATING TAU LEVELS | MAPT, NEFM, PSEN2 | FOXO1 3615/4885NPC1 478/4885RAB9A 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.